These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23734940)

  • 1. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
    Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
    Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Dexamethasone Implant for Treatment of Refractory Behçet Posterior Uveitis: One-year Follow-up Results.
    Coşkun E; Celemler P; Kimyon G; Öner V; Kisacik B; Erbagci I; Onat AM
    Ocul Immunol Inflamm; 2015; 23(6):437-43. PubMed ID: 26470764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.
    Adán A; Hernandez V; Ortiz S; Molina JJ; Pelegrin L; Espinosa G; Sanmartí R
    Int Ophthalmol; 2010 Oct; 30(5):577-81. PubMed ID: 20490893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behçet's disease.
    Ishikawa S; Taguchi M; Muraoka T; Sakurai Y; Kanda T; Takeuchi M
    Br J Ophthalmol; 2014 Nov; 98(11):1508-13. PubMed ID: 24939422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.
    Giansanti F; Barbera ML; Virgili G; Pieri B; Emmi L; Menchini U
    Eur J Ophthalmol; 2004; 14(5):445-8. PubMed ID: 15506610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
    Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
    Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with infliximab for Behçet disease during pregnancy.
    Takayama K; Ishikawa S; Enoki T; Kojima T; Takeuchi M
    Ocul Immunol Inflamm; 2013 Aug; 21(4):321-3. PubMed ID: 23617408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
    Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
    Bawazeer A; Raffa LH; Nizamuddin SH
    Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.